medigraphic.com
Anales de Otorrinolaringología Mexicana

2023, Number 1

<< Back Next >>

Otorrinolaringología 2023; 68 (1)

Response after the first two injections of type A botulinum toxin in vocal folds with adductor spasmodic dysphonia

Estrada-García R, Zubiaur-Gomar FM

Language: Spanish
References: 19
Page: 29-35
PDF size: 197.22 Kb.


ABSTRACT

Objective: To compare a self-reported satisfaction questionnaire with the first two botulinum toxin injections in patients with adductor spasmodic dysphonia.
Materials and Methods: A comparative retrospective study was done in a laryngology private center of Mexico City from March 2011 to July 2021. Patients with spasmodic dysphonia were included and received treatment based on bilateral botulinum toxin vocal fold injections through cricothyroid membrane with electromyography guidance.
Results: Thirty-five subjects were enrolled. Average of units per vocal fold was 2.8 ± 2.1 and 3.4 ± 2.7 in the first and second injections, respectively (p = 0.01). Less patients asked for dosage modification (increased or decreased) in the second injection (23/35) compared to the first (25/35) and an increase in the number of patients that wanted to maintain the same units of botulinum toxin after the first and second injection, 10 to 12, respectively, was also seen.
Conclusions: There was a tendency toward a greater percentage of subjects wanting to maintain their previous botulinum toxin dosage, suggesting greater satisfaction between dosages.


REFERENCES

  1. Schweinfurth JM, Billante M, Courey MS. Risk factorsand demographics in patients with spasmodicdysphonia. Laryngoscope 2002; 112 (2): 220-3. doi:10.1097/00005537-200202000-00004.

  2. Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinumtoxin therapy. Ann Otol Rhinol Laryngol 1991; 100(2): 85-9. doi: 10.1177/000348949110000201.

  3. Marchese MR, D’Alatri L, Bentivoglio AR, Paludetti G.Onabotulinumtoxin A for adductor spasmodic dysphonia(ADSD): Functional results and the role of dosage. Toxicol2018; 155: 38-42. doi: 10.1016/j.toxicon.2018.10.006.

  4. Stachler RJ, Francis DO, Schwartz SR, Damask CC, DigoyGP, Krouse HJ, et al. Clinical Practice Guideline: Hoarseness(Dysphonia) (Update). Otolaryngol Head Neck Surg 2018;158 (1_suppl): S1-S42. doi: 10.1177/0194599817751030.

  5. Mor N, Simonyan K, Blitzer A. Central voice production andpathophysiology of spasmodic dysphonia. Laryngoscope2018; 128 (1): 177-83. doi: 10.1002/lary.26655.

  6. Blitzer A. Spasmodic dysphonia and botulinum toxin: experiencefrom the largest treatment series. Eur J Neurol 2010;17 Suppl 1: 28-30. doi: 10.1111/j.1468-1331.2010.03047.x.

  7. Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG.Spasmodic dysphonia: A review. Part 2: Characterizationof pathophysiology. Otolaryngol Head Neck Surg 2017; 157(4): 558-564. doi: 10.1177/0194599817728465.

  8. Creighton FX, Hapner E, Klein A, Rosen A, Jinnah HA, JohnsMM. Diagnostic delays in spasmodic dysphonia: A call forclinician education. J Voice Off J Voice Found 2015; 29 (5):592-4. doi: 10.1016/j.jvoice.2013.10.022.

  9. Ludlow CL, Bassich CJ, Connor NP, Coulter DC. Phonatorycharacteristics of vocal fold tremor. J Phon 1986; 14 (3-4):509-15.

  10. French G, Bosch JD, Randall DR. Retrospective review of dosingtrends in botulinum toxin injections for the treatmentof adductor spasmodic dysphonia in a long-term cohort. JOtolaryngol Head Neck Surg 2020; 49 (4).doi.org/10.1186/s40463-020-0401-4.

  11. Rosow DE, Parikh P, Vivero RJ, Casiano RR, Lundy DS.Considerations for initial dosing of botulinum toxinin treatment of adductor spasmodic dysphonia. OtolaryngolHead Neck Surg 2013; 148 (6): 1003-6. doi:10.1177/0194599813484685.

  12. Blitzer A, Brin MF, Stewart CF. Botulinum toxin managementof spasmodic dysphonia (laryngeal dystonia):a 12-year experience in more than 900 patients. Laryngoscope2015; 125 (8): 1751-7. doi: 10.1097/00005537-199810000-00003.

  13. Rosow DE, Pechman A, Saint-Victor S, Lo K, Lundy DS,Casiano RR. Factors influencing botulinum toxin doseinstability in spasmodic dysphonia patients. J Voice 2015;29 (3): 352-5. doi: 10.1016/j.jvoice.2014.08.011.

  14. Shoffel-Havakuk H, Rosow DE, Lava CX, Hapner ER, JohnsMM. Common practices in botulinum toxin injectionfor spasmodic dysphonia treatment: A national survey.Laryngoscope 2019; 129 (7): 1650-6. doi: 10.1002/lary.27696.

  15. Holden PK, Vokes DE, Taylor MB, Till JA, CrumleyRL. Long-term botulinum toxin dose consistency fortreatment of adductor spasmodic dysphonia. AnnOtol Rhinol Laryngol 2007; 116 (12): 891-6. doi:10.1177/000348940711601204.

  16. Gibbs SR, Blitzer A. Botulinum toxin for the treatment ofspasmodic dysphonia. Otolaryngol Clin North Am 2000; 33(4): 879-94. doi: 10.1016/s0030-6665(05)70249-8.

  17. Birkent H, Maronian N, Waugh P, Merati AL, Perkel D,Hillel AD. Dosage changes in patients with long-termbotulinum toxin use for laryngeal dystonia. OtolaryngolHead Neck Surg 2009; 140 (1): 43-7. doi: 10.1016/j.otohns.2008.10.033.

  18. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ.Epidemiology of focal and generalised dystonia in Rochester,Minnesota. Mov Disord 1988; 3 (3): 188-94. doi:10.1002/mds.870030302.

  19. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH,Witt K, et al. Botulinum toxin type A for treating voicetremor. Arch Neurol 2004; 61 (9): 1416-20. doi:10.1001/archneur.61.9.1416.




2020     |     www.medigraphic.com